Articles tagged with Peptides
Researchers at UCL successfully chemically linked amino acids to RNA under conditions that could have occurred on early Earth, a significant step towards understanding the origin of protein synthesis. The study demonstrates how RNA might have first come to control protein synthesis.
A retrospective cohort study found that GLP-1 receptor agonists may reduce overall cancer risk, including lower risks of endometrial and ovarian cancers, among patients with obesity or overweight. However, these medications may also increase the risk of kidney cancer, highlighting the need for longer-term follow-up.
Researchers have discovered that combining antimicrobial peptides from bees and frogs can prevent bacteria from mutating quickly, making them a promising alternative to traditional antibiotics. This finding could lead to safer disease control in livestock and agricultural settings.
Cohort study finds GLP-1 receptor agonist use associated with modestly increased risk of incident diabetic retinopathy; however, those with preexisting DR experience fewer sight-threatening complications. Regular screening and monitoring recommended for all T2D patients on GLP-1 RAs.
A study found that semaglutide and liraglutide use are associated with a higher risk of nonarteritic anterior ischemic optic neuropathy in older patients with type 2 diabetes. The GLP-1 receptor agonists showed varying levels of risk, with liraglutide posing the greatest threat.
Researchers developed a new AI model named BATMAN to improve T cell receptor therapy accuracy. The AI uses a vast database of over 22,000 TCR-peptide interactions to predict peptide binding and identify potential cancer treatments.
The Insilico Medicine recent summer updates webinar introduced new features and functional updates to the company's generative AI platform, including Generative Biologics, Chemistry42, PandaOmics, DORA, and PreciousGPT. These updates aim to accelerate drug discovery and advance life sciences research.
Researchers at the University of Ottawa have made a breakthrough in developing nanoparticles that not only deliver drugs but also contribute to treatment. Their proof-of-concept study shows that particles can be armed with therapeutic potential, revolutionizing the field of nanomedicine.
A recent study published in JAMA Network Open found that glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment was associated with reduced all-cause mortality among older patients with cancer and type 2 diabetes. The survival benefit persisted across various subgroups, including age, sex, and cancer type.
Researchers mapped the frequencies used by Staphylococcus bacteria to communicate, identifying a signal from another species as potent against MRSA. This alternative technique weakens bacterial ability to coordinate attacks on hosts without killing them.
A cohort study found that GLP-1RAs like semaglutide and tirzepatide lower risk of dementia, stroke, and all-cause mortality in adults with type 2 diabetes and obesity. The findings suggest potential neuroprotective benefits beyond glycemic control.
The article provides practical strategies for managing symptoms in patients receiving GLP-1 RAs, focusing on diet and physical activity interventions to support muscle and nutrient preservation. Lifestyle factors remain crucial in GLP-1 RA treatment for effective weight management.
A new study found significant reductions in medication use, symptoms, and procedural interventions with GLP-1 receptor agonist therapy for idiopathic intracranial hypertension. Further prospective studies are needed to confirm these findings.
A research team led by Professor Joongoo Lee successfully expanded ribosome range to produce ring-shaped backbones in proteins. This breakthrough could open doors to novel therapeutics and advanced biomaterials.
The use of GLP-1 receptor agonists among diabetes patients is associated with a higher risk of developing incident neovascular age-related macular degeneration. Further research is needed to understand the underlying mechanisms and trade-offs between benefits and risks.
GLP1-RA treatment is associated with improvements in quality of life, restrained eating, and emotional eating behavior. The treatment also provides reassurance regarding its psychiatric safety profile.
Researchers discovered 500 cryptic peptides found only in pancreatic tumors, which could be targeted by vaccines or engineered T cells to attack the cancer. The peptides were identified using immunopeptidomics and shown to slow down tumor growth in mice.
The study estimates that expanded Medicare coverage for GLP-1RAs would increase access to these treatments and reduce obesity-related comorbidities. However, this would come with substantial costs over a decade, projected at $8 billion, highlighting the need for further price reductions and cost-saving strategies.
Two previously unknown ribosome-arresting peptides (RAPs), PepNL and NanCL, were identified in E. coli, inducing translation arrest through a unique mini-hairpin conformation in the exit tunnel of the ribosome. This discovery provides valuable insights into deciphering the hidden genetic codes within polypeptide sequences.
Aspiro Therapeutics is advancing an innovative inhaled therapy for asthma and COPD using peptidomimetics based on CC16. The treatment aims to address the underlying mechanism driving respiratory conditions, providing a more effective option for patients.
Researchers identify CLE16 peptide as key molecule promoting symbiotic relationship between plants and beneficial soil fungi. Supplementing with this peptide or its fungal equivalent can enhance nutrient exchange and strengthen these traits in crops.
A meta-analysis of randomized clinical trials found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a statistically significant reduction in all-cause dementia. Cardioprotective glucose-lowering therapies, however, did not show an overall reduction in dementia risk.
A study found that spending on GLP-1 RAs increased from 2018 to 2023, with the largest growth rate between 2022 and 2023. The total spending on these medications exceeded $71 billion.
Researchers developed new AI models, InstaNovo and InstaNovo+, to vastly improve accuracy and discovery in protein science. These models excel in tasks such as de novo peptide sequencing, identifying microorganisms, and discovering novel peptides, with implications for personalized medicine, cancer immunology, and beyond.
A team of biologists has discovered an ancient neurohormone called bombesin that controls appetite in humans and other vertebrates. The study also found that bombesin-like neurohormones are present in starfish, revealing a common ancestor of appetite regulation dating back over half a billion years.
Scientists have discovered peptides that bind irreversibly to the transcription factor cJun, permanently blocking its action in cancer cells. The study uses a new screening platform technology and has shown promising results for developing new cancer treatments.
A study found no increased risk of suicidal events among adults taking GLP-1 receptor agonists for diabetes or obesity, but continued monitoring is warranted to identify at-risk patients. The findings ease concerns about these potential adverse effects, allowing extended use of GLP-1 RAs.
Researchers developed CeSPIACE, a 39-amino-acid peptide drug candidate that binds to the spike protein, blocking viral entry. It demonstrates strong binding to major SARS-CoV-2 variants and shows efficacy against multiple strains in vivo and in vitro experiments.
Researchers have developed a new method to deliver antibiotics directly into the bladder tissue, eliminating over 90% of bacteria from the bladder. The nanogel-based drug delivery system shows promise in treating UTIs and could potentially lead to an eventual cure.
A newly discovered peptide called BRP has been found to rival semaglutide (Ozempic) in suppressing appetite and reducing body weight. Unlike Ozempic, BRP acts through a separate metabolic pathway, activating different neurons in the brain, which may offer a more targeted approach to body weight reduction.
Researchers have developed a palladium-mediated reaction to precisely modify peptides and proteins, overcoming challenges in bioconjugation. The method targets dehydroalanine-containing peptides and proteins, enabling efficient synthesis of structurally unique peptides.
A new drug screening method developed by Tampere University has found biologically active molecules that target specific tissues, potentially solving delivery issues in cancer and brain diseases. The method uses phage display and microdialysis to identify peptides with tissue-homing and penetration capabilities.
Camille Bilodeau's project uses AI and molecular simulations to design peptide-covered surfaces for targeted applications, including new medicines, water desalination, and semiconductor manufacturing. Her research group aims to develop a rapid predictive tool to understand surface-water interactions of tethered peptides.
Scientists have identified peptides that can capture and hold microplastics, providing a potential solution for removing these tiny plastic particles from environments. The method combines biophysical modeling, molecular dynamics, quantum computing, and reinforcement learning to optimize the binding of plastics to the peptides.
Sodium-glucose cotransporter-2 inhibitors and GLP-1RAs show reduced risk of moderate/severe COPD exacerbations compared to dipeptidyl peptidase 4 inhibitors. This finding may inform glucose-lowering medication prescribing for patients with type 2 diabetes and active COPD.
A systematic review and network meta-analysis of 601 trials revealed that SGLT2 inhibitors were more cardioprotective in older adults, while GLP-1 receptor agonists offered greater benefits to younger patients. These findings suggest personalized treatment approaches for type 2 diabetes based on age and sex.
A cohort study found that patients without type 2 diabetes had higher discontinuation rates and lower reinitiation rates of GLP-1 receptor agonist therapy. Inequities in access and adherence to effective treatments exacerbate disparities in obesity.
The study found a significant increase in obesity drug prescriptions from 0.76 million in July 2017 to 1.5 million in February 2024, mirroring rising public online search activity for semaglutide and tirzepatide. This correlation highlights the real-time association between public awareness and prescription trends.
Researchers at Terasaki Institute develop lipopeptide hydrogels to deliver peptide-based cancer vaccines, demonstrating sustained release and enhanced immune cell uptake. The system shows promise in overcoming limitations of traditional peptide-based vaccines.
Researchers have developed a groundbreaking approach using specially designed peptides to improve drug formulations, significantly enhancing anti-tumor efficacy in leukemia models. The innovative method achieves high drug loadings and optimizes delivery to targeted areas, holding significant potential for treating various diseases.
A large population-based analysis found that genetic variants in the GLP1R gene are associated with cardiometabolic traits and behavioral changes, such as risk-taking behavior and anxiety. These findings suggest that any observed behavioral changes with GLP1RA medications are unlikely to be a direct result of the medication.
Research from Edith Cowan University reveals camel milk contains more naturally occurring bioactive peptides than cow's milk, potentially providing anti-hypertensive properties and improving digestion. This hypoallergenic alternative has the potential to reduce cardiovascular disease risk and offer a viable option for those with dairy ...
A large international study of GLP1-RA users and dipeptidyl peptidase-4 inhibitors (DPP-4i) found no evidence that GLP1-RA use is associated with an increased risk of thyroid cancer. The study, published in the Thyroid journal, analyzed data from 92,497 GLP1-RA users and 2,484,408 DPP-4i users.
Researchers at Children's Hospital of Philadelphia and Stanford University have developed a new immunotherapy platform called TRACeR-I, which can more accurately recognize a wide variety of surface proteins expressed by cancer cells. This improved recognition enables the body's own immune system to target cancer cells more effectively.
Adult obesity trends in the US have declined for the first time in more than a decade, according to recent data. The South region experienced the largest decreases in body mass index and obesity prevalence, despite also facing high COVID-19 mortality rates among obese individuals.
Researchers from Institute of Science Tokyo develop a new approach to produce four-stranded β-sheets with precisely controlled number of strands, overcoming challenges of fibril aggregation and isomeric variation. This breakthrough could advance biotechnology and nanotechnology applications.
Researchers found a powerful antioxidant in Deinococcus radiodurans that combines with manganese to protect against radiation damage. The discovery could lead to synthetic antioxidants tailored for human needs, protecting astronauts and preparing for radiation emergencies.
A new study developed an innovative approach to combat antibiotic-resistant bacteria by tagging them with a chimeric agent that activates the immune system towards them. This tagging technique helps the immune system recognize and eliminate elusive pathogens, offering a promising new direction for fighting drug-resistant infections.
The discontinuation of GLP-1 RAs has significant clinical implications, including reduced glucose control and increased cardiovascular risk. Long-term adherence to these therapies is crucial for optimal patient outcomes.
Researchers developed a sustainable, high-performance material suitable for packaging and biomedical devices by exploiting the mechanical properties of cellulose nanofibres. Adding small peptides improves their mechanical performance and water-resistance.
Scientists have developed a polymer-based therapeutic for Huntington’s disease, which disrupts protein interactions to preserve cell health. The treatment successfully rescued neurons and reversed symptoms in mouse studies, showing promise as a potential delay or reduction of disease onset.
A team of researchers at the University of Toronto has developed a rapid screening system to identify compounds that can stop the growth of amyloid proteins. The study found 40 compounds that demonstrate the ability to inhibit amyloid formation, providing a promising lead for future disease treatments.
A cross-sectional study found a significant increase in GLP-1 receptor agonist (RA) use as anti-obesity medications from 2022 to 2023. Meanwhile, the rate of metabolic bariatric surgery decreased by 25.6% during the same period. These findings suggest a potential shift in treatment strategies for obesity management
Researchers at the Hebrew University of Jerusalem have developed a highly selective inhibitor for Matrix Metallopeptidase 7 (MMP7), an enzyme crucial for cancer spread and progression. The novel peptide D'20 demonstrates remarkable stability and selectivity, targeting MMP7 while leaving similar enzymes unaffected.
Researchers at Northwestern University developed soft, sustainable electroactive materials using peptides and a snippet of plastic. These materials can store energy or record digital information and have potential applications in low-power electronics, sensors, and medical implants.
A study from Goethe University Frankfurt reveals that venomous crustaceans, specifically remipede crabs in Mexican cenote caves, contain a variety of toxins with pharmacological potential. The xibalbines peptides effectively inhibit potassium channels and activate signaling pathways involved in pain sensitization.
A new study reveals thaumatin, a widely used natural sweetener, produces bitter peptides that stimulate acid secretion and influence inflammatory reactions in human stomach cells. The peptides also show anti-inflammatory effects by reducing pro-inflammatory interleukin 17A release via the TAS2R16 bitter taste receptor.
A new study sheds light on the chemistry surrounding peptide helices, which are crucial for protein structure and function. The research details how different amino acid sequences influence helical structures, offering potential for designing new molecules in medicine and biotechnology.
Researchers at NYU Abu Dhabi have developed nanoscale covalent organic frameworks (nCOFs) modified with peptides to treat triple-negative breast cancer. The COFs selectively release drug cargo within the acidic environment of tumors, improving treatment effectiveness and minimizing side effects.
Researchers developed an algorithm to analyze peptides in infected wounds, revealing unique biomarkers that enable earlier and more accurate diagnoses. This breakthrough method uses mass spectrometry and machine learning to diagnose infections in just a few minutes.